MTOR and acute myeloid leukemia: To confirm the on-target molecular mechanisms of MLN0128, we assessed inhibition of AKT/mTOR signaling in three AML cell lines (OCI-AML3, U937, and MV4-11) and primary AML samples by Western blot analysis.